DLL3 and acute myeloid leukemia: In a recent AML study, Notch 3, 4 and Jagged-1 were associated with an adverse cytogeneic risk, Notch 2 and 3 expression were associated with increased relapse following induction therapy, Notch 4 and Jagged-2 were associated with increased relapse following allogeneic stem cell transplantation, while Notch 4, Jagged-2 and DLL-3 expression were associated with a poor OS in AML patients, further supporting the biomarker and therapeutic potential of Notch in this cancer [60].